Relmada Therapeutics (RLMD) Set to Announce Quarterly Earnings on Wednesday

Relmada Therapeutics (NASDAQ:RLMD) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.04. On average, analysts expect Relmada Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relmada Therapeutics Trading Down 0.3 %

NASDAQ:RLMD traded down $0.01 on Tuesday, hitting $3.84. The company’s stock had a trading volume of 31,315 shares, compared to its average volume of 235,228. Relmada Therapeutics has a one year low of $2.36 and a one year high of $7.22. The stock has a fifty day moving average of $4.90 and a two-hundred day moving average of $4.01. The firm has a market capitalization of $115.85 million, a P/E ratio of -1.15 and a beta of 0.27.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.